A physiologically based modeling strategy during preclinical CNS drug development

Molecular Pharmaceutics

Volumn 11, Issue 3, 2014, Pages 836-848

  Ball, Kathryn ^a   Bouzom, François ^a   Scherrmann, Jean Michel ^b,c   Walther, Bernard ^a   Declèves, Xavier ^b,c  

^a INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

^b CNRS   (France)

^c INSERM   (France)

Author keywords

blood brain barrier; blood cerebrospinal fluid barrier; CNS; drug development; IVIVE; Kp,brain; Kp,uu,brain; membrane; PBPK model; permeability

Indexed keywords

2,3 DIHYDRO 3,4 CYCLOPENTANO 1,2,4 BENZOTHIADIAZINE 1,1 DIOXIDE; ATOMOXETINE; PARACETAMOL; ADRENERGIC RECEPTOR AFFECTING AGENT; ANTIPYRETIC AGENT; BENZOTHIADIAZINE DERIVATIVE; CENTRAL NERVOUS SYSTEM AGENTS; PROPYLAMINE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN CELL; BRAIN SIZE; CELLULAR DISTRIBUTION; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DECISION TREE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BRAIN LEVEL; DRUG CONCENTRATION; DRUG DEVELOPMENT; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG PENETRATION; EXTRACELLULAR FLUID; MICRODIALYSIS; MOLECULAR MODEL; NONHUMAN; PHYSIOLOGICALLY BASED PHARMACOKINETIC MODEL; PRIORITY JOURNAL; RAT; SENSITIVITY ANALYSIS; ANIMAL; BRAIN; DRUG EFFECTS; HUMAN; METABOLISM; PHYSIOLOGY; THEORETICAL MODEL;

ACETAMINOPHEN; ADRENERGIC UPTAKE INHIBITORS; ANIMALS; ANTIPYRETICS; BENZOTHIADIAZINES; BLOOD-BRAIN BARRIER; BRAIN; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM AGENTS; DECISION TREES; DRUG DISCOVERY; EXTRACELLULAR FLUID; HUMANS; MICRODIALYSIS; MODELS, THEORETICAL; PROPYLAMINES; RATS;

EID: 84901743141     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp400533q     Document Type: Article

References (38)

1. Morgan, P.; Van Der Graaf, P. H.; Arrowsmith, J.; Feltner, D. E.; Drummond, K. S.; Wegner, C. D.; Street, S. D. A. Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival Drug Discovery Today 2012, 17, 419-24
2. Smith, D. A.; Di, L.; Kerns, E. H. The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery Nat. Rev. Drug Discovery 2010, 9, 929-39
3. Palmer, A. M.; Alavijeh, M. S. Translational CNS medicines research Drug Discovery Today 2012, 17, 1068-78
4. Ball, K.; Bouzom, F.; Scherrmann, J.-M.; Walther, B.; Declèves, X. Physiologically Based Pharmacokinetic Modeling of Drug Penetration Across the Blood-Brain Barrier-Towards a Mechanistic IVIVE-Based Approach AAPS J. 2013, 15 (4) 913-32
5. Liu, X.; Smith, B. J.; Chen, C.; Callegari, E.; Becker, S. L.; Chen, X.; Cianfrogna, J.; Doran, A. C.; Doran, S. D.; Gibbs, J. P.; Hosea, N.; Liu, J.; Nelson, F. R.; Szewc, M. A.; Van Deusen, J. Use of a physiologically based pharmacokinetic model to study the time to reach brain equilibrium: an experimental analysis of the role of blood-brain barrier permeability, plasma protein binding, and brain tissue binding J. Pharmacol. Exp. Ther. 2005, 313, 1254-62
6. Kielbasa, W.; Kalvass, J. C.; Stratford, R. Microdialysis evaluation of atomoxetine brain penetration and central nervous system pharmacokinetics in rats Drug Metab. Dispos. 2009, 37, 137-42
7. Kielbasa, W.; Stratford, R. E. Exploratory translational modeling approach in drug development to predict human brain pharmacokinetics and pharmacologically relevant clinical doses Drug Metab. Dispos. 2012, 40, 877-83
8. Ball, K.; Bouzom, F.; Scherrmann, J.; Walther, B.; Declèves, X. Development of a physiologically based pharmacokinetic model for the rat central nervous system and determination of an in vitro-in vivo scaling methodology for the blood-brain barrier permeability of two transporter substrates, morphine and oxycodone J. Pharm. Sci. 2012, 101, 4277-92
9. Collins, J. M.; Dedrick, R. L. Distributed model for drug delivery to CSF and brain tissue Am. J. Physiol. 1983, 245, R303-10
10. Suzuki, H.; Terasaki, T.; Sugiyama, Y. Role of efflux transport across the blood-brain barrier and blood-cerebrospinal fluid barrier on the disposition of xenobiotics in the central nervous system Adv. Drug Delivery Rev. 1997, 25, 257-85
11. Fridén, M.; Bergström, F.; Wan, H.; Rehngren, M.; Ahlin, G.; Hammarlund-Udenaes, M.; Bredberg, U. Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods Drug Metab. Dispos. 2011, 39, 353-62
12. MacIntyre, A. C.; Cutler, D. J. The potential role of lysosomes in tissue distribution of weak bases Biopharm. Drug Dispos. 1988, 9, 513-26
13. Westerhout, J.; Ploeger, B.; Smeets, J.; Danhof, M.; de Lange, E. C. M. Physiologically based pharmacokinetic modeling to investigate regional brain distribution kinetics in rats AAPS J. 2012, 14, 543-53
14. Bourasset, F.; Bernard, K.; Muñoz, C.; Genissel, P.; Scherrmann, J. Neuropharmacokinetics of a new alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) modulator, S18986 [(S)-2,3-dihydro-[3,4]cyclopentano-1,2, 4-benzothiadiazine-1,1-dioxide], in the rat Drug Metab. Dispos. 2005, 33, 1137-43
15. Swanson, L. W. Mapping the human brain: past, present, and future Trends Neurosci. 1995, 18, 471-4
16. Summerfield, S. G.; Lucas, A. J.; Porter, R. A.; Jeffrey, P.; Gunn, R. N.; Read, K. R.; Stevens, A. J.; Metcalf, A. C.; Osuna, M. C.; Kilford, P. J.; Passchier, J.; Ruffo, A. D. Toward an improved prediction of human in vivo brain penetration Xenobiotica 2008, 38, 1518-35
17. Dyck, B.; Tamiya, J.; Jovic, F.; Pick, R. R.; Bradbury, M. J.; O'Brien, J.; Wen, J.; Johns, M.; Madan, A.; Fleck, B. A; Foster, A. C.; Li, B.; Zhang, M.; Tran, J. A; Vickers, T.; Grey, J.; Saunders, J.; Chen, C. Characterization of thien-2-yl 1S,2R-milnacipran analogues as potent norepinephrine/serotonin transporter inhibitors for the treatment of neuropathic pain J. Med. Chem. 2008, 51, 7265-72
18. Faassen, F.; Vogel, G.; Spanings, H.; Vromans, H. Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs Int. J. Pharm. 2003, 263, 113-22
19. Reichel, A. The role of blood-brain barrier studies in the pharmaceutical industry Curr. Drug Metab. 2006, 7, 183-203
20. Cao, Y.; Jusko, W. J. Applications of minimal physiologically-based pharmacokinetic models J. Pharmacokinet. Pharmacodyn. 2012, 39, 711-23
21. Ghersi-Egea, J.-F.; Mönkkönen, K. S.; Schmitt, C.; Honnorat, J.; Fèvre-Montange, M.; Strazielle, N. Blood-brain interfaces and cerebral drug bioavailability Rev. Neurol. 2009, 165, 1029-38
22. Johanson, C.; Stopa, E.; McMillan, P.; Roth, D.; Funk, J.; Krinke, G. The distributional nexus of choroid plexus to cerebrospinal fluid, ependyma and brain: toxicologic/pathologic phenomena, periventricular destabilization, and lesion spread Toxicol. Pathol. 2011, 39, 186-212
23. Del Bigio, M. R. The ependyma: a protective barrier between brain and cerebrospinal fluid Glia 1995, 14, 1-13
24. Shen, D. D.; Artru, A. A; Adkison, K. K. Principles and applicability of CSF sampling for the assessment of CNS drug delivery and pharmacodynamics Adv. Drug Delivery Rev. 2004, 56, 1825-57
25. Kodaira, H.; Kusuhara, H.; Fujita, T.; Ushiki, J.; Fuse, E.; Sugiyama, Y. Quantitative evaluation of the impact of active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier on the predictability of the unbound concentrations of drugs in the brain using cerebrospinal fluid concentration as a J. Pharmacol. Exp. Ther. 2011, 339, 935-44
26. Xiao, G.; Black, C.; Hetu, G.; Sands, E.; Wang, J.; Caputo, R.; Rohde, E.; Gan, L.-S. L. Cerebrospinal fluid can be used as a surrogate to assess brain exposures of breast cancer resistance protein and P-glycoprotein substrates Drug Metab. Dispos. 2012, 40, 779-87
27. Kazmi, F.; Hensley, T.; Pope, C.; Funk, R. S.; Loewen, G. J.; Buckley, D. B.; Parkinson, A. Lysosomal sequestration (trapping) of lipophilic amine (cationic amphiphilic) drugs in immortalized human hepatocytes (Fa2N-4 cells) Drug Metab. Dispos. 2013, 41, 897-905
28. Rodgers, T.; Leahy, D.; Rowland, M. Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases J. Pharm. Sci. 2005, 94, 1259-76
29. Rodgers, T.; Rowland, M. Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions J. Pharm. Sci. 2006, 95, 1238-57
30. Poulin, P.; Ekins, S.; Theil, F.-P. A hybrid approach to advancing quantitative prediction of tissue distribution of basic drugs in human Toxicol. Appl. Pharmacol. 2011, 250, 194-212
31. Perrière, N.; Yousif, S.; Cazaubon, S.; Chaverot, N.; Bourasset, F.; Cisternino, S.; Declèves, X.; Hori, S.; Terasaki, T.; Deli, M.; Scherrmann, J.-M.; Temsamani, J.; Roux, F.; Couraud, P.-O. A functional in vitro model of rat blood-brain barrier for molecular analysis of efflux transporters Brain Res. 2007, 1150, 1-13
32. Hoshi, Y.; Uchida, Y.; Tachikawa, M.; Inoue, T.; Ohtsuki, S.; Terasaki, T. Quantitative atlas of blood-brain barrier transporters, receptors, and tight junction proteins in rats and common marmoset J. Pharm. Sci. 2013, 102 (9) 3343-55
33. Avdeef, A.; Tam, K. Y. How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability? J. Med. Chem. 2010, 53, 3566-84
34. Avdeef, A. How well can in vitro brain microcapillary endothelial cell models predict rodent in vivo blood-brain barrier permeability? Eur. J. Pharm. Sci. 2011, 43, 109-24
35. Deo, A. K.; Theil, F.-P.; Nicolas, J.-M. Confounding parameters in preclinical assessment of blood-brain barrier permeation: an overview with emphasis on species differences and effect of disease States Mol. Pharmaceutics 2013, 10, 1581-95
36. Uchida, Y.; Ohtsuki, S.; Katsukura, Y.; Ikeda, C.; Suzuki, T.; Kamiie, J.; Terasaki, T. Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors J. Neurochem. 2011, 117, 333-45
37. Fenstermacher, J.; Gross, P.; Sposito, N.; Acuff, V.; Pettersen, S.; Gruber, K. Structural and functional variations in capillary systems within the brain Ann. N.Y. Acad. Sci. 1988, 529, 21-30
38. Dastmalchi, S.; Rashidi, M. R.; Rassi, M. Simultaneous determination of the pKa and octanol/water partition coefficient (Pm) of acetaminophen J. Sch. Pharm., Med. Sci. Univ. Tehran. 1995, 4, 7-14